Skip to content

US · RCKT · BIOTECHNOLOGY

Rocket Pharmaceuticals, Inc. (RCKT) intrinsic value and stock valuation

$1.95as of 2026-11-21 · Mkt cap 394.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rocket Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values RCKT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RCKT’s statements →

Rocket Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cranbury, NJ 08512 rocketpharma.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-223.12M
20122025
Free cash flow
-$-190.45M
20122025
Total equity
$277.2M-11.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-228.52M-$-273.2M-$-259.66M-$-224.34M-$-167.25M
Net income-$-223.12M-$-258.75M-$-245.59M-$-221.86M-$-169.07M
EPSd-$-2.01M-$-2.73M-$-2.92M-$-3.26M-$-2.67M
Operating cash flow-$-190.01M-$-209.72M-$-194.92M-$-178.14M-$-121.16M
Capital expenditure-$-440K-$-5.86M-$-16.47M-$-8.62M-$-7.71M
Free cash flow-$-190.45M-$-215.59M-$-211.39M-$-186.76M-$-128.88M
Total assets$330.5M$527.7M$566.3M$551.8M$497M
Total debt$24.9M$25.5M$25M$22.9M$22.6M
Net debt-$-52.68M-$-138.14M-$-30.86M-$-117.65M-$-210.09M
Total equity$277.2M$463.2M$492.6M$489.7M$454.7M
Cash and short-term investments$188.9M$372.3M$373.2M$356.4M$388.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$11M$0.00$0.00$0.00$0.00
Gross profit-$-11.03M$0.00$0.00$0.00$0.00
Research and development expenses$142M$171.2M$186.3M$165.6M$125.5M
Selling, general and administrative expenses$86.5M$102M$73.3M$58.8M$41.8M
Other expenses-$-11.03M$0.00$0.00$0.00$0.00
Operating expenses$217.5M$273.2M$259.7M$224.3M$167.3M
Cost and expenses$228.5M$273.2M$259.7M$224.3M$167.3M
Interest income$10.6M$18.2M$15.9M$3.89M$3.07M
Interest expense$1.89M$1.89M$1.88M$1.91M$5.89M
Depreciation and amortization$11M$9.38M$7.1M$6.27M$5.37M
Ebitda-$-210.21M-$-247.49M-$-236.62M-$-213.69M-$-157.81M
Operating income-$-228.52M-$-273.2M-$-259.66M-$-224.34M-$-167.25M
Total other income/expenses, net$5.39M$14.5M$14.1M$2.48M-$-1.82M
Income before tax-$-223.12M-$-258.75M-$-245.59M-$-221.86M-$-169.07M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-223.12M-$-258.75M-$-245.59M-$-221.86M-$-169.07M
Weighted average shares outstanding$111.1M$94.8M$84M$68.2M$63.2M
Weighted average diluted shares outstanding$111.1M$94.8M$84M$68.2M$63.2M
Balance sheet
20252024202320222021
Cash and short-term investments$188.9M$372.3M$373.2M$356.4M$388.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$192.7M$378.2M$378.2M$364.1M$392.1M
Property, plant and equipment, net$71.6M$83.3M$87.6M$77.6M$72.4M
Goodwill and intangible assets$64.3M$64.3M$64.3M$64.9M$30.8M
Long-term investments$1.34M$0.00$34.3M$43.3M$0.00
Total non-current assets$137.7M$149.5M$188.1M$187.8M$105M
Total assets$330.5M$527.7M$566.3M$551.8M$497M
Accounts payable$0.00$1.62M$0.00$0.00$0.00
Short-term debt$2.92M$2.86M$2.72M$2.51M$2.55M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$30.2M$40.7M$48.5M$39.2M$22.2M
Long-term debt$22M$22.6M$22.3M$20.4M$20.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$23M$23.8M$25.3M$23M$20.1M
Capital lease obligations$24.9M$25.5M$25M$22.9M$22.6M
Total liabilities$53.2M$64.5M$73.8M$62.1M$42.3M
Common stock$1.08M$1.06M$900K$790K$650K
Retained earnings-$-1.44B-$-1.22B-$-959.37M-$-713.77M-$-491.91M
Accumulated other comprehensive income (loss)-$-30K$70K$320K-$-360K-$-160K
Total equity$277.2M$463.2M$492.6M$489.7M$454.7M
Total investments$112.7M$208.7M$351.6M$259.2M$156.1M
Total debt$24.9M$25.5M$25M$22.9M$22.6M
Net debt-$-52.68M-$-138.14M-$-30.86M-$-117.65M-$-210.09M
Cash flow statement
20252024202320222021
Net income-$-223.12M-$-258.75M-$-245.59M-$-221.86M-$-169.07M
Depreciation and amortization$11M$9.38M$7.1M$6.27M$5.37M
Stock-based compensation$37.1M$43.9M$39.4M$31M$29.2M
Change in working capital-$-8.3M$1.92M$13.5M$6.08M-$-3.39M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$9.67M-$-4.83M
Net cash provided by operating activities-$-190.01M-$-209.72M-$-194.92M-$-178.14M-$-121.16M
Investments in property, plant and equipment-$-440K-$-5.86M-$-16.47M-$-8.62M-$-7.71M
Acquisitions, net$0.00$0.00$0.00$42.7M$100K
Net cash used for investing activities$103.8M$131.7M-$-98.07M-$-69.33M$18.9M
Common stock issued$0.00$185.7M$208.4M$155.3M$37.7M
Common stock repurchased-$-70K$0.00$0.00-$-50K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$150K$185.7M$208.4M$155.3M$37.7M
Net change in cash-$-86.1M$107.7M-$-84.58M-$-92.18M-$-64.63M
Cash at end of period$78.9M$165M$57.3M$141.9M$234M
Operating cash flow-$-190.01M-$-209.72M-$-194.92M-$-178.14M-$-121.16M
Capital expenditure-$-440K-$-5.86M-$-16.47M-$-8.62M-$-7.71M
Free cash flow-$-190.45M-$-215.59M-$-211.39M-$-186.76M-$-128.88M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rocket Pharmaceuticals, Inc.

        Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

        CEO
        Gaurav D. Shah
        Employees
        202
        Beta
        0.45

        Explore

        Frequently asked questions

        What is the intrinsic value of Rocket Pharmaceuticals, Inc. (RCKT)?

        InvestorsCraft does not currently publish an intrinsic value for RCKT. How the IC value is calculated.

        Is RCKT undervalued?

        InvestorsCraft does not publish an undervaluation signal for RCKT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.